AbbVie Cash on Hand 2010-2024 | ABBV | MacroTrends

AbbVie Cash on Hand 2010-2024 | ABBV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AbbVie cash on hand for the quarter ending September 30, 2024 was $7.285B, a 45.18% decline year-over-year.

AbbVie cash on hand for 2023 was $12.816B, a 38.87% increase from 2022.
AbbVie cash on hand for 2022 was $9.229B, a 6.11% decline from 2021.
AbbVie cash on hand for 2021 was $9.83B, a 15.93% increase from 2020.

AbbVie Cash on Hand 2010-2024 | ABBV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AbbVie cash on hand for 2023 was $12.816B, a 38.87% increase from 2022.
AbbVie cash on hand for 2022 was $9.229B, a 6.11% decline from 2021.
AbbVie cash on hand for 2021 was $9.83B, a 15.93% increase from 2020.

Related Stocks
Company Name	Market Cap
Eli Lilly (LLY)	$692.7B
Novo Nordisk (NVO)	$460.6B
Johnson & Johnson (JNJ)	$368.4B
Merck (MRK)	$244.2B
Novartis AG (NVS)	$211.1B
AstraZeneca (AZN)	$197.8B
Pfizer (PFE)	$142.2B
Sanofi (SNY)	$121.8B
Innoviva (INVA)	$1.2B